TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Vital signs (blood pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximal concentration of rivaroxaban
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Factor Xa activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of crystalloid solutions administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction in FIQ score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: User Performance (UP) evaluation measured by blood glucose level (mg/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: System Accuracy (SA) evaluation measured by blood glucose level (mg/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Detection of Treatment Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RMSE compared to CO-oximetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve 0 to tz (AUC0-tz) of Total Dabigatran
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Measured Concentration (Cmax) of Total Dabigatran in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 28 Day Survival
Endpoint domain: Mortality/survival
Primary endpoint: PBMC Gene Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days off work through sickness absence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Lesion size visualization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of episodes of PLE symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in severity of PLE symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of years of life lost or lived with disabilities
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of years of life lost or lived with disabilities
Endpoint domain: Mortality/survival
Primary endpoint: PDR Peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electromyography Response Amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proprioception Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Electromyography Microvoltage Signal During Walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in end-diastolic dimension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference in tricuspid annular plane systolic excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference in right atrium volume index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference in fraction of area contraction of right ventricle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference in right ventricle global strain rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tricuspid regurgitant volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent of Patients Who Achieved CAI Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pazopanib exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's dietary intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Children's weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma Concentration of Lidocaine and MEGX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cerebrospinal Fluid Insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: gastrointestinal peptide secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Accuracy of tracked ultrasound registration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antithrombotic efficacy of TTP889
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of TTP889
Endpoint domain: Adverse events/effects
Primary endpoint: TOTPAR-8
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: SPID-8
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Forced expiratory flow rate (FEF25-75%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinically Relevant Postoperative Pancreatic Fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Acute CINV Complete Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of Participants With No Pain Immediately After Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Antibiotic-Associated Diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Complete surgical removal of cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Risk of Lung Cancer
Endpoint domain: Mortality/survival
Primary endpoint: Risk of lymphoma
Endpoint domain: Mortality/survival
Primary endpoint: Time to Best Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in composite ADC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diminution of agitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with modified clinical signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with modified biological values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of AEs/SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Total substrate oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial plasma insulin and glucose response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dietary fat oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pro-inflammatory cytokines in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Presence or absence of an edging to radiolucent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Constant and MURLEY Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HCC conspicuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change Scores of Functional Emotional Assessment Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of blood culture contamination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: reduction of anxiety symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in the level of psychological resilience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: International Index of Erectile Function (IIEF-5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Erection Questionnaire (QEQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Premature Ejaculation Diagnostic Tool (PEDT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients alive without relapse
Endpoint domain: Mortality/survival
Primary endpoint: Influenza Hemagluttination Inhibition Titers Against H3N2 Perth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Influenza Hemagluttination Inhibition Titers Against Pandemic H1N1 Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline of probing depth (PD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCtau (area under the plasma concentration-time curve for a dosing interval)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tmax (time to attain Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ctrough (plasma concentration at the end of a dosing interval)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Anger State
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Multiple Sclerosis (MS) relapses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Glaucoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monosyllabic word in quiet scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estrogen Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sleep Efficiency Measured at Baseline
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Mean Change in Serum Osteocalcin (OC) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Change in Serum Type-1 Collagen Cross-linked N-telopeptide (NTX) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Change in Bone Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Falls Risk Factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathology complete remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal tolerated dose (MTD) of Lenalidomide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of time with intra-esophageal pH <4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fibrosis volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of satiety using objective methods (blood analysis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Assessment of satiety (blood analysis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Assessment of satiety using a subjective method (visual analogue scale)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Trans-pulmonary pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Toxicities of SCH 66336
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose of SCH 66336
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of SCH 66336
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Number of Participants Who Developed Inhibitors Against Factor IX (FIX)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Incremental Recovery of a 50 IU/kg Dose of CSL654 in Previously Untreated Patients (PUPs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained microbiological success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: gut microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: white blood cell
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects Experiencing Dose Limiting Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Apolipoprotein A-I Fractional Catabolic Rate (FCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Apo-A1 Production Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Post-prandial Triglyceride Incremental Area Under the Curve (iAUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: composite endpoint: Stroke, systemic embolism, myocardial infarction, life-threatening bleeding events and vascular death
Endpoint domain: Mortality/survival
Primary endpoint: composite endpoint: Stroke, systemic embolism, myocardial infarction and vascular death
Endpoint domain: Mortality/survival
Primary endpoint: Recommended phase 2 dose (RP2D)
Endpoint domain: Adverse events/effects
Primary endpoint: Best objective Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Smoking Behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the Oswestry Disability Index (ODI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Blood and urinalysis values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Quantity of Oxaliplatin onkovis needed per treatment cycle
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Course of diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standard Uptake Values (SUVs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity Rates of Fused FDG-PET/MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of PET/CT and PET/MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjects' Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: TB diagnostic sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in self-reported social anxiety symptoms
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in clinician-rated social anxiety symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in memory narratives and appraisals
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of participants receiving treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes in plasma glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in hemoglobin A1c level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in level of self reported 5-9 servings of fruits and vegetables
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion with salt sensitivity of blood pressure at baseline via ABPM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion with salt sensitivity of blood pressure after allopurinol via ABPM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Salt sensitivity index at baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Recurrence rate of gastric or duodenal ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Local-regional Control Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of grade 3-5 toxicity during chemotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Patient Compliance with Follow-Up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of recovery from agitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention in outpatient treatment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Pain While Active - 18 hr
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Amount of Narcotic Consumption in the First 24 Hours Post Surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Trabecular Microarchitecture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronary Heart Disease events
Endpoint domain: Mortality/survival
Primary endpoint: Number of Treatment of Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Stress response at birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence and severity of serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Maximum Plasma Concentration (Tmax) of Apremilast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spread of Coloring Solution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ramsy sedation score (RSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Admission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Time to Attain Discharge Criteria
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Ratio of integrated insulin secretion rates (total AUC ISR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Total AUC Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of tumor Standardised Uptake Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Continued Toxicity assessment
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic Assessment of trough levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1st toe blood pressure (strain gauge)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Ankle blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change from Baseline 24h urinary sodium excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Voice quality assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of expression of pfcrt and pfmdr-1 alleles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentrations of 6-TGN and 6-MMPN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of IL-6, NLRP3 and IL-18
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of liver fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Proportion of participants reporting > 95% adherence to both HIV and syphilis PrEP therapies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The proportion of individuals reporting grade 3 or 4 adverse events in the immediate vs. deferred arms
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Nutrition and Physical Activity Policies
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in albumin excretion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: PSA Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to localize in-breast lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Death rates of non-COVID diseases
Endpoint domain: Mortality/survival
Primary endpoint: Rates of stillbirth
Endpoint domain: Mortality/survival
Primary endpoint: Clinical benefit defined as non-progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No dose-limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: No other toxicity requiring termination of treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Complete Pathologic Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Flanker Inhibitory Control and Attention Test Scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Picture Vocabulary Test Scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in List Sorting Working Memory Test Scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Dimensional Change Card Sort Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Pattern Comparison Processing Speed Test Scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Picture Sequence Memory Test v2.1 Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Count of Participants Who Received Influenza Vaccine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cumulative Length of Time on Ventilator
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes